Bing Xu
The First Affiliated Hospital of Xiamen University · The First Aiffiliated hosptical of xiamen University · Department of Hematology, Nanfang Hospital, The Southern Medical University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Bing Xu as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:28 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07783100 · Venetoclax, Chidamide, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Refractory Acute Myeloid LeukemiaThe First Affiliated Hospital of Xiamen University · recruiting · Relapsed or Refractory Acute Myeloid Leukemia · principal investigator
- N/ANCT07778212 · Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCLThe First Affiliated Hospital of Xiamen University · recruiting · DLBCL - Diffuse Large B Cell Lymphoma, Intermediate-High Risk, First-Line · principal investigator
- Ph1NCT06875063 · GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHLThe First Affiliated Hospital of Xiamen University · recruiting · Non-hodgkin Lymphoma, Refractory Lymphoma, Chimeric Antigen Receptor T-cell · principal investigator
- Ph2NCT06827899 · Veneclax, Chidaniline Combined With Azacitidine Followed by Decitabine + MAG Regimen in the Treatment of Elderly Untreated AMLThe First Affiliated Hospital of Xiamen University · recruiting · Acute Myeloid Leukemia · principal investigator
- Ph2NCT06826118 · Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular LymphomaThe First Affiliated Hospital of Xiamen University · recruiting · Lymphoma, Follicular Lymphoma, Refractory Lymphoma · principal investigator
- Ph1NCT06737523 · Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AMLThe First Affiliated Hospital of Xiamen University · recruiting · Acute Myeloid Leukemia, Relapse, Refractory AML · principal investigator
- Ph1NCT06651866 · Dose-escalation Study of D-CMG Regimen for the Treatment of Elderly Newly Diagnosed AML PatientsThe First Affiliated Hospital of Xiamen University · recruiting · Acute Myeloid Leukemia · principal investigator
- Ph2NCT06581640 · Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple MyelomaThe First Affiliated Hospital of Xiamen University · recruiting · Multiple Myeloma, Relapsed/Refractory · principal investigator
- Ph2NCT06553352 · Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular LymphomaThe First Affiliated Hospital of Xiamen University · recruiting · Follicular Lymphoma, Newly Diagnosed · principal investigator
- N/ANCT06478472 · Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local TherapyThe First Affiliated Hospital of Xiamen University · recruiting · Marginal Zone Lymphoma · principal investigator
- Ph2NCT06158399 · AZA Combined With RCHOP in P53-mutated DLBCL.The First Affiliated Hospital of Xiamen University · recruiting · DLBCL - Diffuse Large B Cell Lymphoma, TP53 · principal investigator
- Ph2NCT06151080 · Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FLThe First Affiliated Hospital of Xiamen University · recruiting · DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma · principal investigator
- Ph2NCT06151106 · Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell LymphomaThe First Affiliated Hospital of Xiamen University · recruiting · Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell Lymphoma · principal investigator
- N/ANCT06151119 · 68Ga-FAPI PET/CT Imaging for Diagnosis, Grading, and Efficacy Evaluation of Myelofibrosis.The First Affiliated Hospital of Xiamen University · recruiting · Primary Myelofibrosis · principal investigator
- Ph2NCT05603884 · VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)The First Affiliated Hospital of Xiamen University · recruiting · Leukemia, Myeloid, Acute, AML Stage, Adult · principal investigator
- Ph2NCT05305859 · Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AMLThe First Affiliated Hospital of Xiamen University · recruiting · Leukemia, Myeloid, Acute, Relapsed Adult AML, Refractory Leukemia · principal investigator
- N/ANCT01889407 · Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia PatientsNanfang Hospital, Southern Medical University · unknown · Acute Myeloid Leukemia · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:28 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 21 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in acute myeloid leukemia, ranked by citations from NIH iCite, fetched 2026-11-12 10:28 UTC. The ranking covers the 200 most relevant of 2 PubMed records, and a shared surname and initials can bring in a namesake. All 2 on PubMed
- [Modified FLAG regimen in the management of refractory acute myeloid leukemia].Di Yi Jun Yi Da Xue Xue Bao · 20031 citationsRCR 0.0
- [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].Ai Zheng · 20030 citationsRCR 0.0